Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesBariatric & Obesity ManagementAnthem weight-loss meds Prior Auth Coverage | Open…
    Ask Trek AI about this page
    CurrentAnthemPolicy N/A

    Prior authorization for weight-loss medications

    Customize your policy alerts

    Sign up for all Anthem policy alerts

    Know when Anthem releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This form defines prior authorization requirements and clinical criteria for Medicaid members in Virginia requesting coverage of weight-loss medications (including GLP-1 receptor agonists, orlistat, stimulants, Imcivree®, and related agents). It applies to prescribers submitting PA requests for Anthem/HealthKeepers Medicaid products.

    Policy Summary
    PayerAnthem
    PolicyPrior authorization for weight-loss medications
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionComplete and submit the prior authorization form with required recent documentation (medical status, individualized weight-loss plan, and accurate height/weight within 60 days).
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    6 moInitial auth length (typical)
    BMI ≥30

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Common BMI threshold
    3–6 moTrial durations
    Age ≥6Imcivree min age

    Coverage and Medical Necessity Criteria

    Initial and renewal medical necessity criteria

    Coverage provided when ALL applicable agent-specific criteria and general requirements are met.

    General requirements: Absence of medical contraindications; participation in nutritional counseling and physical activity program unless medically contraindicated; commitment to continue the weight-loss treatment plan; provider attests if obesity is disabling/life‑threatening; written documentation of medical status and individualized weight‑loss plan and accurate height/weight from within the last 60 days.

    From general coverage and documentation requirements

    Agent-specific BMI and age criteria: Phentermine, phendimetrazine (tablet/ER), orlistat, phentermine/topiramate: BMI ≥ 30 kg/m2 OR BMI ≥ 27 kg/m2 with ≥1 weight‑related comorbidity; benzphetamine and diethylpropion (and phentermine/topiramate for certain ages): BMI ≥ 30 kg/m2; Imcivree® (min age 6): BMI ≥ 30 kg/m2 plus genetic confirmation or Bardet‑Biedl syndrome and prescriber specialty requirements; GLP‑1 receptor agonists (Wegovy/Saxenda min age 12, Zepbound min age 18): BMI > 40 kg/m2 if no risk factors OR BMI > 37 kg/m2 with ≥1 risk factor (dyslipidemia, hypertension, or type 2 diabetes).

    Minimum ages per FDA approvals; see genetic and GLP‑1 nodes for additional requirements

    GLP‑1 specific prerequisites: Member has tried and failed one non‑GLP‑1 weight‑loss medication (accepted drug trial definitions apply) OR is intolerant to all non‑GLP‑1 weight‑loss medications; member is not concurrently on another GLP‑1 receptor agonist; member has tried and failed the selected product per the Preferred Drug List when applicable.

    Applies when a GLP‑1 agent is requested; accepted trial durations: GLP‑1 = six months without ≥5% body weight reduction (see definitions)

    Imcivree®‑specific requirements: Prescribed by or in consultation with an endocrinologist or geneticist; member has Bardet‑Biedl syndrome OR confirmed POMC, PCSK1, or LEPR deficiency by genetic test; genetic variants must be interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS).

    Applies when Imcivree® is requested (min age 6)

    Response criteria for renewals: Agent‑specific response required for renewal: stimulants and certain agents – ≥10‑pound weight loss in initial 3 months to extend; orlistat – ≥10‑pound weight loss to extend; GLP‑1 receptor agonists – ≥5% reduction in body weight compared to the most recent authorization to extend; Imcivree® – ≥5% reduction in body weight (or ≥5% of baseline BMI in those with continued growth potential) to extend. Renewals will not be granted once member reaches BMI < 25. Renewals must be submitted within 30 days of prior authorization expiration.

    Renewal thresholds and limits; see authorization lengths for maximum durations and waiting periods

    Coverage is limited when a member has any of the listed contraindications. Providers must confirm no contraindications to use such as uncontrolled hypertension or hyperthyroidism for stimulant-based products. For orlistat, confirm absence of malabsorption syndromes, cholestasis, pregnancy, and lactation. Requests for GLP-1 receptor agonists require no history of eating disorder or acute pancreatitis, and no acute suicidal behavior/ideation, personal or family history of medullary thyroid cancer, or multiple endocrine neoplasia type 2 (MEN2).

    Renewal authorizations will not be granted once a member's BMI is 25. Providers should submit renewal requests within 30 days of the most recent authorization's expiration and include the required drug-specific response documentation; however, no renewals are permitted if the member's BMI has fallen below 25.

    BMI and Related Criteria

    BMI thresholds by agent
    Adult non‑GLP‑1 agents (e.g., phentermine, phendimetrazine, orlistat, phentermine/topiramate)BMI ≥ 30 kg/m2 OR BMI ≥ 27 kg/m2 with ≥1 weight‑related comorbidity (e.g., coronary heart disease, dyslipidemia, hypertension, sleep apnea, type 2 diabetes)
    Younger/alternate formulations (benzphetamine, diethylpropion, phentermine/topiramate ages 12–17)BMI ≥ 30 kg/m2 (minimum ages per FDA approval)
    Imcivree® (pediatric)BMI ≥ 30 kg/m2 plus genetic confirmation (Bardet‑Biedl syndrome OR POMC/PCSK1/LEPR deficiency with variants interpreted as pathogenic, likely pathogenic, or VUS); prescriber is/consults endocrinologist or geneticist
    GLP‑1 receptor agonists (Wegovy/Saxenda/Zepbound)BMI > 40 kg/m2 if no risk factors; OR BMI > 37 kg/m2 with ≥1 risk factor (dyslipidemia, hypertension, or type 2 diabetes)

    Authorization, Documentation, and Submission Requirements

    Denial Risk

    Incomplete information triggers denial

    Incomplete physician-supplied information will result in denial of the request. If the physician does not provide the necessary information, the request will be denied and a fax form requesting additional information will be sent to the prescriber.

    • If additional information is requested, respond promptly to avoid delays.
    Documentation Required

    Required recent documentation

    Written documentation from within the last 60 days is required and must include medical status and an individualized weight-loss plan (specific reduced-calorie meal plan, recommended routine physical activity, and behavioral intervention). Accurate height and weight measurements within the last 60 days must also be provided.

    • Medical status and weight-loss plan dated within 60 days

    Clinical and Program Background

    The prior authorization form is designed to support clinical assessment and document that required behavioral and medical management components are in place before and during pharmacologic weight-loss therapy. Required elements include documentation of an individualized weight-loss plan (a specific reduced-calorie meal plan, recommended routine physical activity, and behavioral intervention), participation in nutritional counseling and a physical activity program unless contraindicated, commitment to continue the weight-loss plan, and accurate height and weight measurements — all documented within the last 60 days.

    Trial Definitions and Terms

    Accepted drug‑trial definitions (agent‑specific)
    Stimulant-class agents (e.g., benzphetamine, diethylpropion, phentermine, phendimetrazine)Accepted trial = 3‑month trial without weight loss of 10 pounds
    OrlistatAccepted trial = 6‑month trial without weight loss of 10 pounds
    GLP‑1 receptor agonistsAccepted trial = 6‑month trial without ≥5% body weight reduction
    Policy Summary
    PayerAnthem
    PolicyPrior authorization for weight-loss medications
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionComplete and submit the prior authorization form with required recent documentation (medical status, individualized weight-loss plan, and accurate height/weight within 60 days).
    SourceLink
    On This Page
    Coverage and Medical Necessity CriteriaBMI and Related CriteriaAuthorization, Documentation, and Submission RequirementsClinical and Program BackgroundTrial Definitions and Terms
  1. Accurate height and weight within 60 days
  2. Summary/details of prior weight-loss treatment plans (diet and exercise) and a copy of the plan
  3. Prior Authorization

    Form completion and submission

    All requested form fields must be completed and the prescriber must sign the form. Incomplete forms will delay PA processing. The completed form and any supporting documentation may be faxed to 844-512-7020. Submission of documentation does not guarantee coverage.

    • Prescriber signature and date required
    • Include drug name, form, strength, dosing frequency, length of therapy, quantity, day supply
    Step Therapy

    Prior non-GLP-1 trial required for GLP-1 agents

    For GLP-1 receptor agonists indicated for weight loss, the member must have tried and failed one of the non-GLP-1 weight-loss medications (or be intolerant to all non-GLP-1 weight-loss medications) as defined by the accepted drug trials (e.g., three- or six-month trials without required weight loss). Member must not be concurrently on another GLP-1 receptor agonist and must have also tried and failed the selected product if applicable per the Preferred Drug List.

    • Definition of accepted drug trial: GLP-1 trial = six-month trial without a body weight reduction of 5%
    • Member intolerant to all non-GLP-1 meds satisfies trial requirement